nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitagliptin—CYP2C8—Ifosfamide—testicular cancer	0.162	0.225	CbGbCtD
Sitagliptin—ABCB1—Dactinomycin—testicular cancer	0.0931	0.129	CbGbCtD
Sitagliptin—CYP2C8—Etoposide—testicular cancer	0.0776	0.108	CbGbCtD
Sitagliptin—CYP3A4—Ifosfamide—testicular cancer	0.0659	0.0912	CbGbCtD
Sitagliptin—ABCB1—Vinblastine—testicular cancer	0.0583	0.0808	CbGbCtD
Sitagliptin—ABCB1—Cisplatin—testicular cancer	0.0535	0.0741	CbGbCtD
Sitagliptin—ABCB1—Etoposide—testicular cancer	0.0526	0.0728	CbGbCtD
Sitagliptin—ABCB1—Doxorubicin—testicular cancer	0.0358	0.0496	CbGbCtD
Sitagliptin—CYP3A4—Vinblastine—testicular cancer	0.035	0.0484	CbGbCtD
Sitagliptin—ABCB1—Methotrexate—testicular cancer	0.0347	0.0481	CbGbCtD
Sitagliptin—CYP3A4—Etoposide—testicular cancer	0.0315	0.0436	CbGbCtD
Sitagliptin—CYP3A4—Doxorubicin—testicular cancer	0.0215	0.0297	CbGbCtD
Sitagliptin—Influenza—Epirubicin—testicular cancer	0.000481	0.00173	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000478	0.00172	CcSEcCtD
Sitagliptin—Skin disorder—Etoposide—testicular cancer	0.000474	0.00171	CcSEcCtD
Sitagliptin—Erectile dysfunction—Methotrexate—testicular cancer	0.000473	0.0017	CcSEcCtD
Sitagliptin—Pancreatitis—Epirubicin—testicular cancer	0.000472	0.0017	CcSEcCtD
Sitagliptin—Abdominal pain upper—Doxorubicin—testicular cancer	0.00047	0.00169	CcSEcCtD
Sitagliptin—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00047	0.00169	CcSEcCtD
Sitagliptin—Breast disorder—Doxorubicin—testicular cancer	0.000465	0.00167	CcSEcCtD
Sitagliptin—Decreased appetite—Cisplatin—testicular cancer	0.000463	0.00167	CcSEcCtD
Sitagliptin—Bronchitis—Epirubicin—testicular cancer	0.000463	0.00166	CcSEcCtD
Sitagliptin—Diarrhoea—Dactinomycin—testicular cancer	0.000461	0.00166	CcSEcCtD
Sitagliptin—Pneumonia—Methotrexate—testicular cancer	0.000461	0.00166	CcSEcCtD
Sitagliptin—Nasopharyngitis—Doxorubicin—testicular cancer	0.000461	0.00166	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00046	0.00165	CcSEcCtD
Sitagliptin—Vomiting—Bleomycin—testicular cancer	0.00046	0.00165	CcSEcCtD
Sitagliptin—Infestation—Methotrexate—testicular cancer	0.000458	0.00165	CcSEcCtD
Sitagliptin—Infestation NOS—Methotrexate—testicular cancer	0.000458	0.00165	CcSEcCtD
Sitagliptin—Depression—Methotrexate—testicular cancer	0.000457	0.00164	CcSEcCtD
Sitagliptin—Rash—Bleomycin—testicular cancer	0.000456	0.00164	CcSEcCtD
Sitagliptin—Pain—Cisplatin—testicular cancer	0.000456	0.00164	CcSEcCtD
Sitagliptin—Dermatitis—Bleomycin—testicular cancer	0.000455	0.00164	CcSEcCtD
Sitagliptin—Hypersensitivity—Ifosfamide—testicular cancer	0.000455	0.00164	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000454	0.00163	CcSEcCtD
Sitagliptin—Renal failure—Methotrexate—testicular cancer	0.000451	0.00162	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000447	0.00161	CcSEcCtD
Sitagliptin—Influenza—Doxorubicin—testicular cancer	0.000445	0.0016	CcSEcCtD
Sitagliptin—Asthenia—Ifosfamide—testicular cancer	0.000443	0.0016	CcSEcCtD
Sitagliptin—Feeling abnormal—Cisplatin—testicular cancer	0.000439	0.00158	CcSEcCtD
Sitagliptin—Weight increased—Epirubicin—testicular cancer	0.000438	0.00158	CcSEcCtD
Sitagliptin—Pancreatitis—Doxorubicin—testicular cancer	0.000436	0.00157	CcSEcCtD
Sitagliptin—Hyperglycaemia—Epirubicin—testicular cancer	0.000434	0.00156	CcSEcCtD
Sitagliptin—Somnolence—Etoposide—testicular cancer	0.000434	0.00156	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Methotrexate—testicular cancer	0.000434	0.00156	CcSEcCtD
Sitagliptin—Pneumonia—Epirubicin—testicular cancer	0.000431	0.00155	CcSEcCtD
Sitagliptin—Nausea—Bleomycin—testicular cancer	0.00043	0.00155	CcSEcCtD
Sitagliptin—Infestation—Epirubicin—testicular cancer	0.000429	0.00154	CcSEcCtD
Sitagliptin—Infestation NOS—Epirubicin—testicular cancer	0.000429	0.00154	CcSEcCtD
Sitagliptin—Vomiting—Dactinomycin—testicular cancer	0.000429	0.00154	CcSEcCtD
Sitagliptin—Bronchitis—Doxorubicin—testicular cancer	0.000428	0.00154	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000425	0.00153	CcSEcCtD
Sitagliptin—Rash—Dactinomycin—testicular cancer	0.000425	0.00153	CcSEcCtD
Sitagliptin—Decreased appetite—Etoposide—testicular cancer	0.000424	0.00153	CcSEcCtD
Sitagliptin—Diarrhoea—Ifosfamide—testicular cancer	0.000423	0.00152	CcSEcCtD
Sitagliptin—Renal failure—Epirubicin—testicular cancer	0.000422	0.00152	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000421	0.00152	CcSEcCtD
Sitagliptin—Fatigue—Etoposide—testicular cancer	0.000421	0.00151	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Epirubicin—testicular cancer	0.00042	0.00151	CcSEcCtD
Sitagliptin—Constipation—Etoposide—testicular cancer	0.000417	0.0015	CcSEcCtD
Sitagliptin—Pain—Etoposide—testicular cancer	0.000417	0.0015	CcSEcCtD
Sitagliptin—Urinary tract infection—Epirubicin—testicular cancer	0.000417	0.0015	CcSEcCtD
Sitagliptin—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000414	0.00149	CcSEcCtD
Sitagliptin—Dizziness—Ifosfamide—testicular cancer	0.000409	0.00147	CcSEcCtD
Sitagliptin—Pharyngitis—Methotrexate—testicular cancer	0.000408	0.00147	CcSEcCtD
Sitagliptin—Urinary tract disorder—Methotrexate—testicular cancer	0.000406	0.00146	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Epirubicin—testicular cancer	0.000406	0.00146	CcSEcCtD
Sitagliptin—Weight increased—Doxorubicin—testicular cancer	0.000405	0.00146	CcSEcCtD
Sitagliptin—Urethral disorder—Methotrexate—testicular cancer	0.000403	0.00145	CcSEcCtD
Sitagliptin—Sinusitis—Epirubicin—testicular cancer	0.000402	0.00145	CcSEcCtD
Sitagliptin—Feeling abnormal—Etoposide—testicular cancer	0.000402	0.00145	CcSEcCtD
Sitagliptin—Hyperglycaemia—Doxorubicin—testicular cancer	0.000402	0.00144	CcSEcCtD
Sitagliptin—Nausea—Dactinomycin—testicular cancer	0.000401	0.00144	CcSEcCtD
Sitagliptin—Pneumonia—Doxorubicin—testicular cancer	0.000399	0.00144	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Etoposide—testicular cancer	0.000399	0.00144	CcSEcCtD
Sitagliptin—Infestation NOS—Doxorubicin—testicular cancer	0.000397	0.00143	CcSEcCtD
Sitagliptin—Infestation—Doxorubicin—testicular cancer	0.000397	0.00143	CcSEcCtD
Sitagliptin—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000394	0.00142	CcSEcCtD
Sitagliptin—Vomiting—Ifosfamide—testicular cancer	0.000393	0.00141	CcSEcCtD
Sitagliptin—Hypersensitivity—Cisplatin—testicular cancer	0.000393	0.00141	CcSEcCtD
Sitagliptin—Renal failure—Doxorubicin—testicular cancer	0.00039	0.0014	CcSEcCtD
Sitagliptin—Rash—Ifosfamide—testicular cancer	0.00039	0.0014	CcSEcCtD
Sitagliptin—Dermatitis—Ifosfamide—testicular cancer	0.000389	0.0014	CcSEcCtD
Sitagliptin—Erythema multiforme—Methotrexate—testicular cancer	0.000389	0.0014	CcSEcCtD
Sitagliptin—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000389	0.0014	CcSEcCtD
Sitagliptin—Urticaria—Etoposide—testicular cancer	0.000388	0.00139	CcSEcCtD
Sitagliptin—Abdominal pain—Etoposide—testicular cancer	0.000386	0.00139	CcSEcCtD
Sitagliptin—Urinary tract infection—Doxorubicin—testicular cancer	0.000386	0.00139	CcSEcCtD
Sitagliptin—Eye disorder—Methotrexate—testicular cancer	0.000385	0.00138	CcSEcCtD
Sitagliptin—Hypoaesthesia—Epirubicin—testicular cancer	0.000383	0.00138	CcSEcCtD
Sitagliptin—Asthenia—Cisplatin—testicular cancer	0.000382	0.00138	CcSEcCtD
Sitagliptin—Pharyngitis—Epirubicin—testicular cancer	0.000382	0.00138	CcSEcCtD
Sitagliptin—Cardiac disorder—Methotrexate—testicular cancer	0.000382	0.00137	CcSEcCtD
Sitagliptin—Urinary tract disorder—Epirubicin—testicular cancer	0.00038	0.00137	CcSEcCtD
Sitagliptin—Oedema peripheral—Epirubicin—testicular cancer	0.000379	0.00136	CcSEcCtD
Sitagliptin—Connective tissue disorder—Epirubicin—testicular cancer	0.000378	0.00136	CcSEcCtD
Sitagliptin—Urethral disorder—Epirubicin—testicular cancer	0.000377	0.00136	CcSEcCtD
Sitagliptin—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000375	0.00135	CcSEcCtD
Sitagliptin—Angiopathy—Methotrexate—testicular cancer	0.000373	0.00134	CcSEcCtD
Sitagliptin—Sinusitis—Doxorubicin—testicular cancer	0.000372	0.00134	CcSEcCtD
Sitagliptin—Immune system disorder—Methotrexate—testicular cancer	0.000372	0.00134	CcSEcCtD
Sitagliptin—Mediastinal disorder—Methotrexate—testicular cancer	0.000371	0.00133	CcSEcCtD
Sitagliptin—Nausea—Ifosfamide—testicular cancer	0.000367	0.00132	CcSEcCtD
Sitagliptin—Diarrhoea—Cisplatin—testicular cancer	0.000365	0.00131	CcSEcCtD
Sitagliptin—Erythema multiforme—Epirubicin—testicular cancer	0.000364	0.00131	CcSEcCtD
Sitagliptin—Mental disorder—Methotrexate—testicular cancer	0.000361	0.0013	CcSEcCtD
Sitagliptin—Eye disorder—Epirubicin—testicular cancer	0.00036	0.00129	CcSEcCtD
Sitagliptin—Hypersensitivity—Etoposide—testicular cancer	0.00036	0.00129	CcSEcCtD
Sitagliptin—Malnutrition—Methotrexate—testicular cancer	0.000358	0.00129	CcSEcCtD
Sitagliptin—Cardiac disorder—Epirubicin—testicular cancer	0.000357	0.00129	CcSEcCtD
Sitagliptin—Hypoaesthesia—Doxorubicin—testicular cancer	0.000355	0.00128	CcSEcCtD
Sitagliptin—Pharyngitis—Doxorubicin—testicular cancer	0.000354	0.00127	CcSEcCtD
Sitagliptin—Urinary tract disorder—Doxorubicin—testicular cancer	0.000352	0.00127	CcSEcCtD
Sitagliptin—Oedema peripheral—Doxorubicin—testicular cancer	0.000351	0.00126	CcSEcCtD
Sitagliptin—Asthenia—Etoposide—testicular cancer	0.00035	0.00126	CcSEcCtD
Sitagliptin—Connective tissue disorder—Doxorubicin—testicular cancer	0.00035	0.00126	CcSEcCtD
Sitagliptin—Angiopathy—Epirubicin—testicular cancer	0.000349	0.00126	CcSEcCtD
Sitagliptin—Urethral disorder—Doxorubicin—testicular cancer	0.000349	0.00126	CcSEcCtD
Sitagliptin—Immune system disorder—Epirubicin—testicular cancer	0.000348	0.00125	CcSEcCtD
Sitagliptin—Mediastinal disorder—Epirubicin—testicular cancer	0.000347	0.00125	CcSEcCtD
Sitagliptin—Back pain—Methotrexate—testicular cancer	0.000347	0.00125	CcSEcCtD
Sitagliptin—Vomiting—Cisplatin—testicular cancer	0.000339	0.00122	CcSEcCtD
Sitagliptin—Vision blurred—Methotrexate—testicular cancer	0.000338	0.00121	CcSEcCtD
Sitagliptin—Mental disorder—Epirubicin—testicular cancer	0.000337	0.00121	CcSEcCtD
Sitagliptin—Erythema multiforme—Doxorubicin—testicular cancer	0.000337	0.00121	CcSEcCtD
Sitagliptin—Rash—Cisplatin—testicular cancer	0.000336	0.00121	CcSEcCtD
Sitagliptin—Dermatitis—Cisplatin—testicular cancer	0.000336	0.00121	CcSEcCtD
Sitagliptin—Malnutrition—Epirubicin—testicular cancer	0.000335	0.00121	CcSEcCtD
Sitagliptin—Diarrhoea—Etoposide—testicular cancer	0.000334	0.0012	CcSEcCtD
Sitagliptin—Eye disorder—Doxorubicin—testicular cancer	0.000333	0.0012	CcSEcCtD
Sitagliptin—Ill-defined disorder—Methotrexate—testicular cancer	0.000332	0.0012	CcSEcCtD
Sitagliptin—Cardiac disorder—Doxorubicin—testicular cancer	0.000331	0.00119	CcSEcCtD
Sitagliptin—Flatulence—Epirubicin—testicular cancer	0.00033	0.00119	CcSEcCtD
Sitagliptin—Tension—Epirubicin—testicular cancer	0.000329	0.00118	CcSEcCtD
Sitagliptin—Nervousness—Epirubicin—testicular cancer	0.000326	0.00117	CcSEcCtD
Sitagliptin—Back pain—Epirubicin—testicular cancer	0.000324	0.00117	CcSEcCtD
Sitagliptin—Angiopathy—Doxorubicin—testicular cancer	0.000323	0.00116	CcSEcCtD
Sitagliptin—Malaise—Methotrexate—testicular cancer	0.000323	0.00116	CcSEcCtD
Sitagliptin—Dizziness—Etoposide—testicular cancer	0.000323	0.00116	CcSEcCtD
Sitagliptin—Muscle spasms—Epirubicin—testicular cancer	0.000322	0.00116	CcSEcCtD
Sitagliptin—Immune system disorder—Doxorubicin—testicular cancer	0.000322	0.00116	CcSEcCtD
Sitagliptin—Vertigo—Methotrexate—testicular cancer	0.000322	0.00116	CcSEcCtD
Sitagliptin—Mediastinal disorder—Doxorubicin—testicular cancer	0.000321	0.00116	CcSEcCtD
Sitagliptin—Nausea—Cisplatin—testicular cancer	0.000316	0.00114	CcSEcCtD
Sitagliptin—Vision blurred—Epirubicin—testicular cancer	0.000316	0.00114	CcSEcCtD
Sitagliptin—Cough—Methotrexate—testicular cancer	0.000313	0.00112	CcSEcCtD
Sitagliptin—Mental disorder—Doxorubicin—testicular cancer	0.000312	0.00112	CcSEcCtD
Sitagliptin—Ill-defined disorder—Epirubicin—testicular cancer	0.000311	0.00112	CcSEcCtD
Sitagliptin—Vomiting—Etoposide—testicular cancer	0.00031	0.00112	CcSEcCtD
Sitagliptin—Malnutrition—Doxorubicin—testicular cancer	0.00031	0.00112	CcSEcCtD
Sitagliptin—Rash—Etoposide—testicular cancer	0.000308	0.00111	CcSEcCtD
Sitagliptin—Dermatitis—Etoposide—testicular cancer	0.000307	0.00111	CcSEcCtD
Sitagliptin—Headache—Etoposide—testicular cancer	0.000306	0.0011	CcSEcCtD
Sitagliptin—Flatulence—Doxorubicin—testicular cancer	0.000306	0.0011	CcSEcCtD
Sitagliptin—Arthralgia—Methotrexate—testicular cancer	0.000305	0.0011	CcSEcCtD
Sitagliptin—Myalgia—Methotrexate—testicular cancer	0.000305	0.0011	CcSEcCtD
Sitagliptin—Tension—Doxorubicin—testicular cancer	0.000304	0.0011	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000303	0.00109	CcSEcCtD
Sitagliptin—Malaise—Epirubicin—testicular cancer	0.000302	0.00109	CcSEcCtD
Sitagliptin—Discomfort—Methotrexate—testicular cancer	0.000301	0.00108	CcSEcCtD
Sitagliptin—Nervousness—Doxorubicin—testicular cancer	0.000301	0.00108	CcSEcCtD
Sitagliptin—Vertigo—Epirubicin—testicular cancer	0.000301	0.00108	CcSEcCtD
Sitagliptin—Back pain—Doxorubicin—testicular cancer	0.0003	0.00108	CcSEcCtD
Sitagliptin—Muscle spasms—Doxorubicin—testicular cancer	0.000298	0.00107	CcSEcCtD
Sitagliptin—Cough—Epirubicin—testicular cancer	0.000293	0.00105	CcSEcCtD
Sitagliptin—Anaphylactic shock—Methotrexate—testicular cancer	0.000292	0.00105	CcSEcCtD
Sitagliptin—Vision blurred—Doxorubicin—testicular cancer	0.000292	0.00105	CcSEcCtD
Sitagliptin—Infection—Methotrexate—testicular cancer	0.00029	0.00104	CcSEcCtD
Sitagliptin—Nausea—Etoposide—testicular cancer	0.00029	0.00104	CcSEcCtD
Sitagliptin—Hypertension—Epirubicin—testicular cancer	0.000289	0.00104	CcSEcCtD
Sitagliptin—Ill-defined disorder—Doxorubicin—testicular cancer	0.000288	0.00104	CcSEcCtD
Sitagliptin—Nervous system disorder—Methotrexate—testicular cancer	0.000287	0.00103	CcSEcCtD
Sitagliptin—Arthralgia—Epirubicin—testicular cancer	0.000285	0.00103	CcSEcCtD
Sitagliptin—Myalgia—Epirubicin—testicular cancer	0.000285	0.00103	CcSEcCtD
Sitagliptin—Anxiety—Epirubicin—testicular cancer	0.000284	0.00102	CcSEcCtD
Sitagliptin—Skin disorder—Methotrexate—testicular cancer	0.000284	0.00102	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000283	0.00102	CcSEcCtD
Sitagliptin—Discomfort—Epirubicin—testicular cancer	0.000282	0.00101	CcSEcCtD
Sitagliptin—Malaise—Doxorubicin—testicular cancer	0.00028	0.00101	CcSEcCtD
Sitagliptin—Dry mouth—Epirubicin—testicular cancer	0.000279	0.001	CcSEcCtD
Sitagliptin—Vertigo—Doxorubicin—testicular cancer	0.000279	0.001	CcSEcCtD
Sitagliptin—Anaphylactic shock—Epirubicin—testicular cancer	0.000274	0.000984	CcSEcCtD
Sitagliptin—Infection—Epirubicin—testicular cancer	0.000272	0.000978	CcSEcCtD
Sitagliptin—Cough—Doxorubicin—testicular cancer	0.000271	0.000974	CcSEcCtD
Sitagliptin—Nervous system disorder—Epirubicin—testicular cancer	0.000268	0.000965	CcSEcCtD
Sitagliptin—Hypertension—Doxorubicin—testicular cancer	0.000268	0.000963	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000266	0.000958	CcSEcCtD
Sitagliptin—Skin disorder—Epirubicin—testicular cancer	0.000266	0.000956	CcSEcCtD
Sitagliptin—Insomnia—Methotrexate—testicular cancer	0.000264	0.000951	CcSEcCtD
Sitagliptin—Myalgia—Doxorubicin—testicular cancer	0.000264	0.00095	CcSEcCtD
Sitagliptin—Arthralgia—Doxorubicin—testicular cancer	0.000264	0.00095	CcSEcCtD
Sitagliptin—Anxiety—Doxorubicin—testicular cancer	0.000263	0.000947	CcSEcCtD
Sitagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000262	0.000944	CcSEcCtD
Sitagliptin—Discomfort—Doxorubicin—testicular cancer	0.000261	0.000939	CcSEcCtD
Sitagliptin—Somnolence—Methotrexate—testicular cancer	0.00026	0.000935	CcSEcCtD
Sitagliptin—Dry mouth—Doxorubicin—testicular cancer	0.000258	0.000929	CcSEcCtD
Sitagliptin—Dyspepsia—Methotrexate—testicular cancer	0.000257	0.000926	CcSEcCtD
Sitagliptin—Decreased appetite—Methotrexate—testicular cancer	0.000254	0.000914	CcSEcCtD
Sitagliptin—Anaphylactic shock—Doxorubicin—testicular cancer	0.000253	0.000911	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000252	0.000908	CcSEcCtD
Sitagliptin—Fatigue—Methotrexate—testicular cancer	0.000252	0.000907	CcSEcCtD
Sitagliptin—Infection—Doxorubicin—testicular cancer	0.000251	0.000905	CcSEcCtD
Sitagliptin—Pain—Methotrexate—testicular cancer	0.00025	0.000899	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000249	0.000897	CcSEcCtD
Sitagliptin—Nervous system disorder—Doxorubicin—testicular cancer	0.000248	0.000893	CcSEcCtD
Sitagliptin—Insomnia—Epirubicin—testicular cancer	0.000247	0.00089	CcSEcCtD
Sitagliptin—Skin disorder—Doxorubicin—testicular cancer	0.000246	0.000885	CcSEcCtD
Sitagliptin—Somnolence—Epirubicin—testicular cancer	0.000243	0.000875	CcSEcCtD
Sitagliptin—Feeling abnormal—Methotrexate—testicular cancer	0.000241	0.000867	CcSEcCtD
Sitagliptin—Dyspepsia—Epirubicin—testicular cancer	0.000241	0.000866	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Methotrexate—testicular cancer	0.000239	0.00086	CcSEcCtD
Sitagliptin—Decreased appetite—Epirubicin—testicular cancer	0.000238	0.000856	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000236	0.00085	CcSEcCtD
Sitagliptin—Fatigue—Epirubicin—testicular cancer	0.000236	0.000849	CcSEcCtD
Sitagliptin—Pain—Epirubicin—testicular cancer	0.000234	0.000842	CcSEcCtD
Sitagliptin—Constipation—Epirubicin—testicular cancer	0.000234	0.000842	CcSEcCtD
Sitagliptin—Urticaria—Methotrexate—testicular cancer	0.000232	0.000836	CcSEcCtD
Sitagliptin—Abdominal pain—Methotrexate—testicular cancer	0.000231	0.000831	CcSEcCtD
Sitagliptin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000231	0.00083	CcSEcCtD
Sitagliptin—Insomnia—Doxorubicin—testicular cancer	0.000229	0.000824	CcSEcCtD
Sitagliptin—Feeling abnormal—Epirubicin—testicular cancer	0.000225	0.000811	CcSEcCtD
Sitagliptin—Somnolence—Doxorubicin—testicular cancer	0.000225	0.00081	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000224	0.000805	CcSEcCtD
Sitagliptin—Dyspepsia—Doxorubicin—testicular cancer	0.000223	0.000802	CcSEcCtD
Sitagliptin—Decreased appetite—Doxorubicin—testicular cancer	0.00022	0.000792	CcSEcCtD
Sitagliptin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000219	0.000786	CcSEcCtD
Sitagliptin—Fatigue—Doxorubicin—testicular cancer	0.000218	0.000785	CcSEcCtD
Sitagliptin—Urticaria—Epirubicin—testicular cancer	0.000217	0.000782	CcSEcCtD
Sitagliptin—Pain—Doxorubicin—testicular cancer	0.000216	0.000779	CcSEcCtD
Sitagliptin—Constipation—Doxorubicin—testicular cancer	0.000216	0.000779	CcSEcCtD
Sitagliptin—Abdominal pain—Epirubicin—testicular cancer	0.000216	0.000778	CcSEcCtD
Sitagliptin—Hypersensitivity—Methotrexate—testicular cancer	0.000215	0.000775	CcSEcCtD
Sitagliptin—Asthenia—Methotrexate—testicular cancer	0.00021	0.000755	CcSEcCtD
Sitagliptin—Feeling abnormal—Doxorubicin—testicular cancer	0.000209	0.000751	CcSEcCtD
Sitagliptin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000207	0.000745	CcSEcCtD
Sitagliptin—Hypersensitivity—Epirubicin—testicular cancer	0.000202	0.000725	CcSEcCtD
Sitagliptin—Urticaria—Doxorubicin—testicular cancer	0.000201	0.000724	CcSEcCtD
Sitagliptin—Abdominal pain—Doxorubicin—testicular cancer	0.0002	0.00072	CcSEcCtD
Sitagliptin—Diarrhoea—Methotrexate—testicular cancer	0.0002	0.00072	CcSEcCtD
Sitagliptin—Asthenia—Epirubicin—testicular cancer	0.000196	0.000706	CcSEcCtD
Sitagliptin—Dizziness—Methotrexate—testicular cancer	0.000193	0.000696	CcSEcCtD
Sitagliptin—Diarrhoea—Epirubicin—testicular cancer	0.000187	0.000673	CcSEcCtD
Sitagliptin—Hypersensitivity—Doxorubicin—testicular cancer	0.000187	0.000671	CcSEcCtD
Sitagliptin—Vomiting—Methotrexate—testicular cancer	0.000186	0.000669	CcSEcCtD
Sitagliptin—Rash—Methotrexate—testicular cancer	0.000184	0.000663	CcSEcCtD
Sitagliptin—Dermatitis—Methotrexate—testicular cancer	0.000184	0.000663	CcSEcCtD
Sitagliptin—Headache—Methotrexate—testicular cancer	0.000183	0.000659	CcSEcCtD
Sitagliptin—Asthenia—Doxorubicin—testicular cancer	0.000182	0.000653	CcSEcCtD
Sitagliptin—Dizziness—Epirubicin—testicular cancer	0.000181	0.000651	CcSEcCtD
Sitagliptin—Vomiting—Epirubicin—testicular cancer	0.000174	0.000626	CcSEcCtD
Sitagliptin—Nausea—Methotrexate—testicular cancer	0.000174	0.000625	CcSEcCtD
Sitagliptin—Diarrhoea—Doxorubicin—testicular cancer	0.000173	0.000623	CcSEcCtD
Sitagliptin—Rash—Epirubicin—testicular cancer	0.000173	0.000621	CcSEcCtD
Sitagliptin—Dermatitis—Epirubicin—testicular cancer	0.000172	0.00062	CcSEcCtD
Sitagliptin—Headache—Epirubicin—testicular cancer	0.000171	0.000617	CcSEcCtD
Sitagliptin—Dizziness—Doxorubicin—testicular cancer	0.000167	0.000602	CcSEcCtD
Sitagliptin—Nausea—Epirubicin—testicular cancer	0.000163	0.000585	CcSEcCtD
Sitagliptin—Vomiting—Doxorubicin—testicular cancer	0.000161	0.000579	CcSEcCtD
Sitagliptin—Rash—Doxorubicin—testicular cancer	0.00016	0.000574	CcSEcCtD
Sitagliptin—Dermatitis—Doxorubicin—testicular cancer	0.000159	0.000574	CcSEcCtD
Sitagliptin—Headache—Doxorubicin—testicular cancer	0.000159	0.000571	CcSEcCtD
Sitagliptin—Nausea—Doxorubicin—testicular cancer	0.00015	0.000541	CcSEcCtD
